Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index; 41 of the 109 sources its claims cite were checked for support.
Abstract
BACKGROUND: Disease-associated-microglia (DAM) represent transcriptionally-distinct and neurodegeneration-specific microglial profiles with unclear significance in Alzheimer's disease (AD). An understanding of heterogeneity within DAM and their key regulators may guide pre-clinical experimentation and drug discovery. METHODS: Weighted co-expression network analysis (WGCNA) was applied to existing microglial transcriptomic datasets from neuroinflammatory and neurodegenerative disease mouse models to identify modules of highly co-expressed genes. These modules were contrasted with known signatures of homeostatic microglia and DAM to reveal novel molecular heterogeneity within DAM. Flow cytometric validation studies were performed to confirm existence of distinct DAM sub-populations in AD mouse models predicted by WGCNA. Gene ontology analyses coupled with bioinformatics approaches revealed drug targets and transcriptional regulators of microglial modules predicted to favorably modulate neuroinflammation in AD. These guided in-vivo and in-vitro studies in mouse models of neuroinflammation and neurodegeneration (5xFAD) to determine whether inhibition of pro-inflammatory gene expression and promotion of amyloid clearance was feasible. We determined the human relevance of these findings by integrating our results with AD genome-wide association studies and human AD and non-disease post-mortem brain proteomes. RESULTS: WGCNA applied to microglial gene expression data revealed a transcriptomic framework of microglial activation that predicted distinct pro-inflammatory and anti-inflammatory phenotypes within DAM, which we confirmed in AD and aging models by flow cytometry. Pro-inflammatory DAM emerged earlier in mouse models of AD and were characterized by pro-inflammatory genes (Tlr2, Ptgs2, Il12b, Il1b), surface marker CD44, potassium channel Kv1.3 and regulators (NFkb, Stat1, RelA) while anti-inflammatory DAM expressed phagocytic genes (Igf1, Apoe, Myo1e), surface marker CXCR4 with distinct regulators (LXRα/β, Atf1). As neuro-immunomodulatory strategies, we validated LXRα/β agonism and Kv1.3 blockade by ShK-223 peptide that promoted anti-inflammatory DAM, inhibited pro-inflammatory DAM and augmented Aβ clearance in AD models. Human AD-risk genes were highly represented within homeostatic microglia suggesting causal roles for early microglial dysregulation in AD. Pro-inflammatory DAM proteins were positively associated with neuropathology and preceded cognitive decline confirming the therapeutic relevance of inhibiting pro-inflammatory DAM in AD. CONCLUSIONS: We provide a predictive transcriptomic framework of microglial activation in neurodegeneration that can guide pre-clinical studies to characterize and therapeutically modulate neuroinflammation in AD.
Overview
CoChat Summary
TL;DR
WGCNA of microglial transcriptomes resolved disease-associated microglia (DAM) into pro-inflammatory and anti-inflammatory subsets in Alzheimer’s disease (AD) mouse models, validated by flow cytometry. LXRα/β agonism and Kv1.3 blockade promoted anti-inflammatory DAM, inhibited pro-inflammatory DAM, and augmented Aβ clearance, with human AD relevance.
Key findings
- WGCNA of 43 microarray samples (16,721 genes) identified 19 co-expression modules; AD-associated modules included a pro-inflammatory Magenta module (Ptgs2, Il12b, Tlr2, Il1b; CD44, Kv1.3; NFkB/Stat1/RelA), an anti-inflammatory/phagocytic Yellow module (Igf1, Apoe, Myo1e; CXCR4; LXRα/β/Atf1), and a homeostatic Blue module (Tmem119, P2ry12). Validation in 64 Nanostring samples with 369 common genes replicated these modules.
- In 6–8 mo 5xFAD mice, CD11c+ DAM were ≈50% of CD11b+ CNS immune cells versus <10% in WT; flow cytometry confirmed CD44+, CXCR4+, double-positive, and double-negative DAM subsets with age-dependent trajectories that were augmented in 5xFAD.
- LXR agonist T0901317 (30 mg/kg i.p. twice weekly for 2 weeks) produced nearly two-fold increases in CXCR4+CD44− anti-inflammatory DAM and increased fibrillar Aβ42 phagocytosis. ShK-223 (100 nM in vitro; 100 μg/kg i.p.) inhibited LPS-induced Ptgs2/Il1b, augmented Kcnj2/Nceh1/Timp2, promoted Aβ phagocytosis and Lamp1 co-localization, and after 3–6 mo treatment lowered hippocampal Aβ plaque burden/size and peri-plaque Iba1 in 5xFAD mice.
- Human relevance: AD GWAS hits were enriched in the homeostatic Blue module (p = 0.005; Bin1, Cnn2, Picalm, Sorl1), and pro-inflammatory DAM proteins were positively associated with neuropathology and preceded cognitive decline in 47 BLSA post-mortem brains (20 AD, 14 asymptomatic AD, 13 controls).
Methods
- WGCNA was applied to existing GEO microarray datasets of purified CD11b+ microglia: 43 arrays from WT, TREM2−/−, 5xFAD, TREM2−/−/5xFAD, APP/PS1, and LPS/IL4-treated cells; data were batch-corrected and analyzed for 16,721 genes. External validation used 64 Nanostring microglial samples and 369 common genes.
- Flow cytometry and functional assays used acutely isolated CNS immune cells from WT, 5xFAD, and aging mice; markers included CD11b, CD45, CD11c, CD44, CXCR4, and Kv1.3 detected with ShK-F6CA. Ex vivo fluorescent Aβ42 phagocytosis, RT-qPCR, immunohistochemistry, BV2 microglial assays, and HEK293 Kv1.3 transfection were also performed.
- In vivo studies used female 5xFAD and C57BL/6 mice; acute neuroinflammation was induced with i.p. LPS, LXR agonist T0901317 was given at 30 mg/kg twice weekly for 2 weeks, and ShK-223 was given at 100 μg/kg i.p. twice weekly from 3 to 6 mo (n = 10/group) with behavior and Aβ quantitation. Statistics used ANOVA with Tukey’s HSD and p ≤ 0.05.
Limitations
- Stated: existing RNAseq microglial transcriptomes were not included because of lower depth of coverage and inability to sufficiently overcome batch effects when combining microarray and RNAseq data.
- Stated: most DAM did not express high levels of either CD44 or CXCR4, suggesting additional complexity within DAM may not have been revealed by the flow cytometry panel.
- Evident: therapeutic and mechanistic conclusions rely largely on mouse models and in vitro assays; human validation is associative (GWAS enrichment and post-mortem proteomics), and the human BLSA proteomics methods are noted as “available online … and will be published subsequently.”
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 Microglial co-expression modules recapitulate homeostatic and DAM profiles and predict heterogeneity within DAM. a 2D-representation of trait-associated WGCNA modules using viSNE. Space between two clusters of genes is an arbitrary representation of dissimilarity or anti-correlation between expression patterns. b Mapping of DAM and homeostatic signature genes to WGCNA modules shows clustering of DAM genes to Yellow and Magenta modules and of Homeostatic genes to the Blue module. Genes shown in Grey represent those that were either not classified as DAM or homeostatic or were not identified by single cell RNAseq [9]. c Key transcriptional regulators, membrane-associated drug targets and predicted functional phenotypes of Blue, Magenta and Yellow AD-associated microglial modules (also see Additional file 7)](https://figures.cochat.ai/paper-figures/4e55ae09c71444b8a23ba927d3576a6c/identification-and-therapeutic-modulation-of-a-pro-inflammatory-subset-of-figure-2.jpg)






![Fig. 9 Identification of AD-risk genes as key members of homeostatic, pro-inflammatory DAM and anti-inflammatory DAM modules. a Enrichment analysis of GWAS-identified AD risk genes in mouse microglial modules (1234 genes identified by MAGMA were used for this analysis [34]). An enrichment score of ≥1.96 (red line) corresponds to significant enrichment (p < 0.05). b-d AD GWAS hits specific to (b) Blue (homeostatic), (c) Yellow (anti-inflammatory DAM) and (d) Magenta (pro-inflammatory DAM) modules. Top 5 genes based on strength of disease association (X-axis: -log10 p-value) are highlighted by a gray silhouette and top 5 genes based on module membership (kME, Y-axis) are shown (also see Additional file 5: Table S5, Additional file 6: Table S6). e-h Analyses performed using quantitative proteomic data obtained from 47 post-mortem human frontal cortices (BLSA, n = 20 confirmed AD cases with cognitive decline, n = 13 controls without any AD pathology and n = 14 cases with AD pathology without cognitive symptoms). e Overlap of mouse modules [Blue/homeostatic, Yellow/anti-inflammatory DAM, Magenta/pro-inflammatory DAM, Purple (homeostatic), Cyan (IL4-upregulated module) and Midnightblue (LPS-upregulated module)] with human protein modules by hypergeometric one-tailed Fisher-exact test. Color intensity indicates strength of significance after Benjamini-Hochberg FDR correction. Strongest FDR-corrected p-values (0.075) were seen for overlap between Yellow and Magenta mouse microglial modules with M2 (unadjusted p = 0.0013), M4 (unadjusted p = 0.0014) and M35 (unadjusted p = 0.0014) human proteomic modules. Y-axis: Mouse WGCNA modules; X-axis: Protein BLSA modules. Correlations between BLSA modules with CERAD and Braak neuropathological grades of AD are shown. f Distribution of mouse microglial module hub genes (kME ≥ 0.90) in human BLSA AD proteome. g Comparison of aggregate expression of Magenta, Yellow and Blue mouse microglial modules in control, asymptomatic AD and clinical AD. Modules with ≥5 hub genes (kME ≥ 0.8) were included. Median module expression was calculated and compared across groups. h Normalized protein expression data of top three proteins from the pro-inflammatory Magenta module (CD44, Bst2 and Nampt) are shown](https://figures.cochat.ai/paper-figures/9778f53da8384f72be405a2522903481/identification-and-therapeutic-modulation-of-a-pro-inflammatory-subset-of-figure-9.jpg)

Verification
Claims the paper makes
16 Valid · 5 Not valid · 33 Not checked · 122 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Within these three AD modules, we observed enrichment of pro-inflammatory genes in the Magenta module (Ptgs2, Il12b, Tlr2, Hif1a, Cd69, Il1b, Cxcl16 and Irg1) and anti-inflammatory and phagocytic genes in the Yellow module (Igf1, Dpp7, Apoe, Spp1, Cd200r4 and Lpl) [38] while the Blue module contained several homeostatic microglial genes (Tmem119, P2ry12, Mtss1 and Tgfbr1, Fig. 2d) [39].”
§ Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease > Results > Co-expression network analysis of microglial gene expression reveals a landscape of diverse and functionally distinct microglial activation states in AD mouse models
What the sources say
- Partly supportedcites [39] Bennett ML Bennett FC Liddelow SA Ajami B Zamanian JL Fernhoff NB Mulinyawe SB Bohlen CJ Adil A Tucker A New tools for studying microglia in the mouse and human CNS Proc Natl Acad Sci U S A 2016 113 E1738 E1746 10.1073/pnas.1525528113 26884166 PMC4812770 sourceExperimental — accuracy not yet measured
Our copy of Bennett et al. supports three of the four genes: Tmem119 and P2ry12 are named among the seven highly expressed microglia-enriched candidates ('Tmem119 mRNA Expression Is Highly Enriched in the CNS and Specific to Most or all Microglia', p. ~E1740-1), both are listed among microglia-enriched transcripts down-regulated by LPS activation ('Other Analyses: Microglial Activation...', p. ~E1744), and Tgfbr1 appears in the Tmem119 co-expression cluster of 'genes associated with leukocyte development, differentiation, and homeostasis' ('Microglial Maturation Occurs by P14 and Correlates with Tmem119', p. ~E1744). Mtss1 is not mentioned anywhere in our copy (searched: Mtss1, microglia-enriched gene list, homeostatic microglial markers), so that gene's inclusion in the homeostatic set is unsupported by this source. The 'Blue module' itself is the citing paper's own co-expression analysis and is not attributed content. (LLM, conf=0.78)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, global microglial depletion in AD mouse models resulted in a protective effect on synaptic health, independent of amyloid β [18, 19].”
§ Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease > Background
What the sources say
- Supportedcites [18] Spangenberg EE Lee RJ Najafi AR Rice RA Elmore MR Blurton-Jones M West BL Green KN Eliminating microglia in Alzheimer’s mice prevents neuronal loss without modulating amyloid-beta pathology Brain 2016 139 1265 1281 10.1093/brain/aww016 26921617 PMC5006229 source
The Introduction reports that eliminating microglia in 5xfAD mice reversed dendritic spine loss without changing amyloid-β levels or plaque load. The Discussion also reports recovery of mushroom spines after microglial elimination. Page numbers are not provided in our copy. (LLM, conf=0.92)
- Partly supportedcites [19] Han J Harris RA Zhang XM An updated assessment of microglia depletion: current concepts and future directions Mol Brain 2017 10 25 10.1186/s13041-017-0307-x 28629387 PMC5477141 sourceExperimental — accuracy not yet measured
Table 1 in “Pharmacological treatment for microglia elimination” reports that microglial depletion in Alzheimer’s mice prevented neuronal loss. Reference 65 identifies the reported finding as occurring without a change in amyloid-beta pathology. Neither passage reports protection of synaptic health specifically, so that part of the claim is unsupported by this copy. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“While single-cell transcriptomic studies have not clarified molecular or functional heterogeneity within DAM [9], meta-analyses and network-based approaches applied to deeper bulk microglial transcriptomes have indicated greater diversity within microglia in neurodegeneration [10, 13].”
§ Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease > Background
What the sources say
- Could not verifycites [9] Keren-Shaul H Spinrad A Weiner A Matcovitch-Natan O Dvir-Szternfeld R Ulland TK David E Baruch K Lara-Astaiso D Toth B A unique microglia type associated with restricting development of Alzheimer’s disease Cell 2017 169 1276 1290 10.1016/j.cell.2017.05.018 28602351 sourceExperimental — accuracy not yet measured
The Results describe single-cell analysis that distinguishes homeostatic microglia, an intermediate state, and DAM, including differences in their gene-expression programs. Those passages address the transition toward DAM, but do not say whether molecular or functional heterogeneity within the DAM group was—or was not—clarified. No page numbers are available in our copy. (LLM, conf=0.70)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“While single-cell transcriptomic studies have not clarified molecular or functional heterogeneity within DAM [9], meta-analyses and network-based approaches applied to deeper bulk microglial transcriptomes have indicated greater diversity within microglia in neurodegeneration [10, 13].”
§ Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease > Background
What the sources say
- Supportedcites [10] Friedman BA Srinivasan K Ayalon G Meilandt WJ Lin H Huntley MA Cao Y Lee SH Haddick PCG Ngu H Diverse brain myeloid expression profiles reveal distinct microglial activation states and aspects of Alzheimer’s disease not evident in mouse models Cell Rep 2018 22 832 847 10.1016/j.celrep.2017.12.066 29346778 source
The Introduction describes a meta-analysis of microglial and brain-myeloid expression profiles, including neurodegenerative models, that yielded distinct co-regulated gene modules. The Discussion reports that these modules identified independent microglial activation states in an Alzheimer’s mouse model, supporting the claim of greater diversity. This paper supports the meta-analysis component of the jointly cited clause; its described method is hierarchical clustering rather than an explicitly named network-based approach. (LLM, conf=0.88)
- Partly supportedcites [13] Holtman IR Raj DD Miller JA Schaafsma W Yin Z Brouwer N Wes PD Moller T Orre M Kamphuis W Induction of a common microglia gene expression signature by aging and neurodegenerative conditions: a co-expression meta-analysis Acta Neuropathol Commun 2015 3 31 10.1186/s40478-015-0203-5 26001565 PMC4489356 sourceExperimental — accuracy not yet measured
The Introduction (page not provided) describes a WGCNA meta-analysis of microglial transcriptomes, and the Results section “Specific expression profiles for aged, Ercc1, App-Ps1, and Sod1 microglia” identifies both a common profile and mouse-model-specific gene-expression components. This supports diversity of transcriptional responses across models, but does not establish greater diversity among microglia within a neurodegenerative condition. (LLM, conf=0.82)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“CD11c (Itgax) was chosen as a general marker of DAM based on existing single-cell RNAseq and confirmatory studies in human brain [9, 45].”
§ Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease > Results > Confirmation of pro-inflammatory and anti-inflammatory DAM profiles in AD mouse models
What the sources say
- Partly supportedcites [9] Keren-Shaul H Spinrad A Weiner A Matcovitch-Natan O Dvir-Szternfeld R Ulland TK David E Baruch K Lara-Astaiso D Toth B A unique microglia type associated with restricting development of Alzheimer’s disease Cell 2017 169 1276 1290 10.1016/j.cell.2017.05.018 28602351 sourceExperimental — accuracy not yet measured
The Results identify Itgax (CD11c) as a potential DAM marker from single-cell RNA-seq in mice and report enrichment of DAM among CD11c-positive cells. The human postmortem-brain validation in the Results uses Lpl, not CD11c. The paper also cautions that CD11c-positive cells are heterogeneous, limiting its use as a general marker. (LLM, conf=0.88)
- Not checked yetcites [45] Kamphuis W Kooijman L Schetters S Orre M Hol EM Transcriptional profiling of CD11c-positive microglia accumulating around amyloid plaques in a mouse model for Alzheimer’s disease Biochim Biophys Acta 1862 2016 1847 1860 27425031
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
103 more claims · 7 with their cited sources checked
Create a free account to see all 176 claims and to verify the 68 references still open.
- It may state two separate claims as one. 57
- Probably not a substantial claim. 19
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This module was enriched in AD genetic risk factors and in microglia and astrocyte protein markers associated with an anti-inflammatory state, suggesting that the biological functions it represents serve a protective role in AD.”
From Large-scale proteomic analysis of Alzheimer’s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation (2020) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The neurodegeneration-related state is controlled by APOE, and agonists of LXR promoted this anti-inflammatory state and microglial phagocytosis of Aβ42 in vitro (Rangaraju et al., 2018).”
From Alzheimer's-associated PU.1 expression levels regulate microglial inflammatory response (2021) · cites this paper as Rangaraju et al., 2018
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Importantly, NF-kB also increases in AD brain [144], and NF-kB signaling modulates microglia by inducing a more inflammatory, disease-associated and cytotoxic state, while also contributing to TAU spreading [145, 146].”
From microRNA-132 attenuates inflammation in induced pluripotent stem cell-derived microglia from Alzheimer’s disease patients (2026) · cites this paper as [146]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Indeed, co-expression network analysis of transcriptomic changes in mouse models of AD revealed distinct states of DAM with pro- and anti-inflammatory profiles (Rangaraju et al., 2018).”
From Alzheimer's-associated PU.1 expression levels regulate microglial inflammatory response (2021) · cites this paper as Rangaraju et al., 2018
The cited source says what the claim attributes to it.
In the citing paper
“other microglial phenotypes beyond the DAM/MGnD have been discovered in murine models of CNS pathology [106, 264]”
From Microglia and monocytes in inflammatory CNS disease: integrating phenotype and function (2022) · cites this paper as [264]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease > Results > Promotion of anti-inflammatory DAM and Aβ phagocytosis by LXRα/β agonists in AD mouse models
“We treated 10–12 mo old 5xFAD mice with the LXR agonist T0901317 (or vehicle) using a twice-weekly i.p. dosing regimen for 2 weeks”
§ Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease > Results > Promotion of anti-inflammatory DAM and Aβ phagocytosis by LXRα/β agonists in AD mouse models
“a Experimental design: 6–7 mo 5xFAD mice (females, n = 4/group) received either vehicle (20% DMSO) or a LXR α/β agonist T0901317 (30 mg/kg i.p. daily × 2 weeks)”
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease > Methods > Human BLSA brain samples and fisher exact test analyses for module overlap
“A hypergeometric two-tailed Fisher’s exact test was used to determine significant overlap between the mouse microglial transcriptomic modules and BLSA proteome modules [34].”
§ Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease > Results > Genetic and pathological links of microglia subtypes in human AD brain
“e Overlap of mouse modules [Blue/homeostatic, Yellow/anti-inflammatory DAM, Magenta/pro-inflammatory DAM, Purple (homeostatic), Cyan (IL4-upregulated module) and Midnightblue (LPS-upregulated module)] with human protein modules by hypergeometric one-tailed Fisher-exact test.”
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease > Methods > Animals
“In some experiments, 5xFAD mice received i.p. doses of T0901317 (30 mg/kg) twice a week for 2 weeks.”
§ Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease > Results > Promotion of anti-inflammatory DAM and Aβ phagocytosis by LXRα/β agonists in AD mouse models
“a Experimental design: 6–7 mo 5xFAD mice (females, n = 4/group) received either vehicle (20% DMSO) or a LXR α/β agonist T0901317 (30 mg/kg i.p. daily × 2 weeks)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease > Results > Genetic and pathological links of microglia subtypes in human AD brain
“h Normalized protein expression data of top three proteins from the pro-inflammatory Magenta module (CD44, Bst2 and Nampt) are shown”
§ Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease > Results > Genetic and pathological links of microglia subtypes in human AD brain
“Normalized expression data of the top 3 pro-inflammatory DAM hub genes (CD44, Cst2 and Nampt) identified in the human brain proteome are shown in Fig. 9h”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease > Results > Validation of Kv1.3 channels as specific regulators of pro-inflammatory DAM responses and neuropathology in AD mouse models
“In HEK293 cells, we confirmed that ShK-F6CA binding was only seen in cells transfected with pcDNA3.1-Kv1.3 but not with empty vector (Fig. 7a).”
§ Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease > Methods > Transient transfection of HEK293 cells
“Transient transfections with either pRC/CMV vector or pRC/CMV-mKv1.3 (a kind gift from Dr. Heike Wulff, UC Davis) or sham were performed for 24 h using 1 μg of plasmid DNA per well.”
Citations
Cites
Analyzing real-time PCR data by the comparative CT method
Schmittgen, T. D., & Livak, K. J. (2008) · Nature Protocols · doi:10.1038/nprot.2008.73 · Cited by 26,190
A General Framework for Weighted Gene Co-Expression Network Analysis
Zhang, B., & Horvath, S. (2005) · Statistical Applications in Genetics and Molecular Biology · doi:10.2202/1544-6115.1128 · Cited by 5,684 · cited 1×
“Differences in gene co-expression may indicate common upstream regulation, functional relatedness and/or restriction to same cell type or cellular compartment [34, 44].”
BackgroundA Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease
Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T. K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.018 · Cited by 5,493
Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K. N., et al. (2006) · Science · doi:10.1126/science.1132939 · Cited by 5,257
Zhang, Y., Chen, K., Sloan, S. A., Bennett, M. L., Scholze, A. R., O'Keeffe, S., Phatnani, H. P., Guarnieri, P., Caneda, C., Ruderisch, N., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.1860-14.2014 · Cited by 4,875
MAGMA: Generalized Gene-Set Analysis of GWAS Data
de Leeuw, C. A., Mooij, J. M., Heskes, T., & Posthuma, D. (2015) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1004219 · Cited by 3,653 · cited 7×
“In the pro-inflammatory DAM module, we identified Treml2 as the gene with highest module membership associated with AD risk.”
BackgroundMethodInfluentialOakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 1×
“Flow cytometric studies informed by WGCNA results confirmed distinct pro-inflammatory and anti-inflammatory subpopulations and suggested additional heterogeneity within DAM in aging and the 5xFAD model of AD pathology [24].”
ResultHyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092
Krasemann, S., Madore, C., Cialic, R., Baufeld, C., Calcagno, N., El Fatimy, R., Beckers, L., O’Loughlin, E., Xu, Y., Fanek, Z., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.08.008 · Cited by 2,979 · cited 3×
“To determine the validity of our results, we performed an external validation of WGCNA using existing microglial transcriptomic studies (Nanostring, n = 64 samples, 369 common genes per sample) of purified microglia isolated from WT and aging mice (2 mo–17 mo) as well as from mouse models of neuroinflammation (LPS tre…”
MethodResultVariant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558
Self-citation
Cited by
Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies
Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C.-C., & Bu, G. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0228-7 · Cited by 1,425
Johnson, E. C. B., Dammer, E. B., Duong, D. M., Ping, L., Zhou, M., Yin, L., Higginbotham, L. A., Guajardo, A., White, B., Troncoso, J. C., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0815-6 · Cited by 1,001
Self-citationMolecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease
Guo, T., Zhang, D., Zeng, Y., Huang, T. Y., Xu, H., & Zhao, Y. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00391-7 · Cited by 994
The Semantics of Microglia Activation: Neuroinflammation, Homeostasis, and Stress
Woodburn, S. C., Bollinger, J. L., & Wohleb, E. S. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02309-6 · Cited by 783
Metadata
- Authors
- Rangaraju, S., Dammer, E. B., Raza, S. A., Rathakrishnan, P., Xiao, H., Gao, T., Duong, D. M., Pennington, M. W., Lah, J. J., Seyfried, N. T., & Levey, A. I.
- Affiliations
- Emory University (US)
- Peptides International (United States) (US)
- Corresponding author
- Rangaraju, Srikant
- ORCID
- Venue
- Molecular Neurodegeneration
- Published
- 2018-05-21
- Volume
- 13
- Issue
- 1
- Pages
- 24-24
- ISSN
- 1750-1326 (ISSN-L)
- PMC
- PMC5963076
- OpenAlex
- W2805185070
- Semantic Scholar
- a977893adea584d249e433834b5e75b14b560849
- Cited by
- 430
- References
- 70
- Citations by year
- 2026: 34 · 2025: 56 · 2024: 71 · 2023: 60 · 2022: 64 · 2021: 73 · 2020: 39 · 2019: 21 · 2018: 9
- FWCI
- 15.93
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- Molecular Neurodegeneration (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institute on Aging (P50 AG025688)
- American Brain Foundation (28301)
- Alzheimer's Association (37102)
- National Institute of Neurological Disorders and Stroke (K08-NS099474-1, P30 NS055077)
- National Institutes of Health (AG046161)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
- Keywords
- disease-associated microglia, Alzheimer's disease, microglial heterogeneity, pro-inflammatory microglia, anti-inflammatory microglia, neuroinflammation, amyloid-beta clearance, microglial transcriptome, 5xFAD mice, CD44, CXCR4
- MeSH terms
- Alzheimer Disease, Animals, Humans, Inflammation, Microglia, Mice, Genome-Wide Association Study, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease. https://app.cochat.ai/papers/10.1186/s13024-018-0254-8
- The paper
- Rangaraju, S., Dammer, E. B., Raza, S. A., Rathakrishnan, P., Xiao, H., Gao, T., Duong, D. M., Pennington, M. W., Lah, J. J., Seyfried, N. T., & Levey, A. I. (2018). Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease. Molecular Neurodegeneration. https://doi.org/10.1186/s13024-018-0254-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.